ReviewCureus2024
Effectiveness of Pfizer Vaccine BNT162b2 Against SARS-CoV-2 in Americans 16 and Older: A Systematic Review.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review evaluates the efficacy and long-term effectiveness of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) across diverse clinical and observational settings within the United States in Americans aged 16 and older. We conducted an extensive literature search utilizing various types of studies to assess the vaccine's performance in preventing symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes. Our initial search in PubMed on March 14, 2022, yielded 6,725 potentially relevant articles, with 26 undergoing full-text assessment and eight meeting the inclusion criteria. To incorporate the most up-to-date findings, a secondary search was conducted on July 6, 2024, using improved and refined Medical Subject Headings (MeSH) terms within the PubMed and Scopus databases. This expanded approach resulted in 78 potentially relevant articles from PubMed and 1,567 from Scopus, with 40 articles undergoing full-text assessment and an additional 14 articles meeting the inclusion criteria. Early clinical trials reported initial vaccine effectiveness (VE) up to 95% with sustained immunity in various populations. Observational studies and systematic reviews further confirmed VE above 90% against symptomatic infections and highlighted nearly complete protection against hospitalizations and deaths. Recent research underscores the critical role of booster doses in maintaining high VE, especially against emerging variants, showing restored effectiveness up to 95% and supporting their strategic importance in ongoing pandemic responses. Despite observed waning immunity and breakthrough infections, the BNT162b2 vaccine continues to exhibit robust protection across different demographic groups and under varying epidemiological conditions. Our findings advocate for continuous booster updates and adaptive vaccination strategies to manage emerging SARS-CoV-2 variants, reinforcing the pivotal role of mRNA vaccine technology in addressing global health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.